A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

Clinical trial NCT06039683 · COMPLETED

Trial details

NCT number: NCT06039683
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2022-12-31
Primary completion: 2024-07-04
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.